Yipinhong PharmaceuticalLtd
Market Cap
CN¥7.5b
Last Updated
2021/04/11 09:17 UTC
Data Sources
Company Financials
Executive Summary
Yipinhong Pharmaceutical Co.,Ltd, together with its subsidiaries, engages in the research and development, production, and sale of pharmaceutical products. More Details
Rewards
Risk Analysis
Snowflake Analysis
Flawless balance sheet with proven track record.
Share Price & News
How has Yipinhong PharmaceuticalLtd's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: 300723 is not significantly more volatile than the rest of CN stocks over the past 3 months, typically moving +/- 6% a week.
Volatility Over Time: 300723's weekly volatility (6%) has been stable over the past year.
Market Performance
7 Day Return
-0.1%
300723
-0.1%
CN Pharmaceuticals
-1.1%
CN Market
1 Year Return
10.5%
300723
15.8%
CN Pharmaceuticals
28.4%
CN Market
Return vs Industry: 300723 underperformed the CN Pharmaceuticals industry which returned 15.8% over the past year.
Return vs Market: 300723 underperformed the CN Market which returned 28.4% over the past year.
Shareholder returns
| 300723 | Industry | Market | |
|---|---|---|---|
| 7 Day | -0.1% | -0.1% | -1.1% |
| 30 Day | -3.4% | 3.9% | 1.0% |
| 90 Day | 21.6% | -5.4% | -5.8% |
| 1 Year | 11.0%10.5% | 16.9%15.8% | 30.4%28.4% |
| 3 Year | 10.0%8.6% | 25.2%20.7% | 25.9%19.9% |
| 5 Year | n/a | 41.6%34.1% | 23.6%15.5% |
Long-Term Price Volatility Vs. Market
How volatile is Yipinhong PharmaceuticalLtd's share price compared to the market and industry in the last 5 years?
Simply Wall St News
No news available
Valuation
Is Yipinhong PharmaceuticalLtd undervalued compared to its fair value and its price relative to the market?
33.38x
Price to Earnings (PE) ratio
Share Price vs. Fair Value
Below Fair Value: 300723 (CN¥47.73) is trading above our estimate of fair value (CN¥4.99)
Significantly Below Fair Value: 300723 is trading above our estimate of fair value.
Price To Earnings Ratio
PE vs Industry: 300723 is poor value based on its PE Ratio (33.4x) compared to the CN Pharmaceuticals industry average (31.2x).
PE vs Market: 300723 is good value based on its PE Ratio (33.4x) compared to the CN market (33.9x).
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate 300723's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: 300723 is overvalued based on its PB Ratio (4.8x) compared to the CN Pharmaceuticals industry average (2.7x).
Future Growth
How is Yipinhong PharmaceuticalLtd forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?
24.3%
Forecasted Pharmaceuticals & Biotech industry annual growth in earnings
In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Yipinhong PharmaceuticalLtd has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.
This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.
Past Performance
How has Yipinhong PharmaceuticalLtd performed over the past 5 years?
9.9%
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: 300723 has a high level of non-cash earnings.
Growing Profit Margin: 300723's current net profit margins (13.5%) are higher than last year (8.8%).
Past Earnings Growth Analysis
Earnings Trend: 300723's earnings have grown by 9.9% per year over the past 5 years.
Accelerating Growth: 300723's earnings growth over the past year (57.1%) exceeds its 5-year average (9.9% per year).
Earnings vs Industry: 300723 earnings growth over the past year (57.1%) exceeded the Pharmaceuticals industry 10.8%.
Return on Equity
High ROE: 300723's Return on Equity (15%) is considered low.
Financial Health
How is Yipinhong PharmaceuticalLtd's financial position?
Financial Position Analysis
Short Term Liabilities: 300723's short term assets (CN¥1.2B) exceed its short term liabilities (CN¥556.8M).
Long Term Liabilities: 300723's short term assets (CN¥1.2B) exceed its long term liabilities (CN¥93.3M).
Debt to Equity History and Analysis
Debt Level: 300723's debt to equity ratio (19.4%) is considered satisfactory.
Reducing Debt: 300723's debt to equity ratio has reduced from 176.6% to 19.4% over the past 5 years.
Debt Coverage: 300723's debt is well covered by operating cash flow (94.9%).
Interest Coverage: 300723 earns more interest than it pays, so coverage of interest payments is not a concern.
Balance Sheet
Dividend
What is Yipinhong PharmaceuticalLtd current dividend yield, its reliability and sustainability?
0.52%
Current Dividend Yield
Dividend Yield vs Market
Notable Dividend: 300723's dividend (0.52%) is higher than the bottom 25% of dividend payers in the CN market (0.43%).
High Dividend: 300723's dividend (0.52%) is low compared to the top 25% of dividend payers in the CN market (1.81%).
Stability and Growth of Payments
Stable Dividend: Whilst dividend payments have been stable, 300723 has been paying a dividend for less than 10 years.
Growing Dividend: 300723's dividend payments have increased, but the company has only paid a dividend for 3 years.
Current Payout to Shareholders
Dividend Coverage: With its low payout ratio (17.5%), 300723's dividend payments are well covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: Insufficient data to determine if a dividend will be paid in 3 years and that it will be covered by earnings.
Next Steps
Management
How experienced are the management team and are they aligned to shareholders interests?
CEO
Hanxiong Li (46 yo)
no data
Tenure
Mr. Hanxiong Li serves as Chairman of the Board of Directors and General Manager at Yipinhong Pharmaceutical Co., Ltd. Mr. Li serves as Vice Chairman of Professional Committee of Pharmaceutical Clinical Re...
Ownership
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Ownership Breakdown
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
Top Shareholders
Company Information
Yipinhong Pharmaceutical Co.,Ltd's company bio, employee growth, exchange listings and data sources
Key Information
- Name: Yipinhong Pharmaceutical Co.,Ltd
- Ticker: 300723
- Exchange: SZSE
- Founded: 2002
- Industry: Pharmaceuticals
- Sector: Pharmaceuticals & Biotech
- Market Cap: CN¥7.531b
- Shares outstanding: 157.78m
- Website: https://www.gdyph.com
Number of Employees
Location
- Yipinhong Pharmaceutical Co.,Ltd
- Star International Building
- 17th Floor Tower
- Guangzhou
- Guangdong Province
- 510623
- China
Listings
Biography
Yipinhong Pharmaceutical Co.,Ltd, together with its subsidiaries, engages in the research and development, production, and sale of pharmaceutical products. It offers anti-infection, pediatric, cardiovascul...
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2021/04/11 09:17 |
| End of Day Share Price | 2021/04/09 00:00 |
| Earnings | 2020/12/31 |
| Annual Earnings | 2020/12/31 |
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.